[1]揭嘉慧,张 颖.卵巢癌与非编码RNA研究进展[J].医学信息,2019,(05):39-42.[doi:10.3969/j.issn.1006-1959.2019.05.014]
 JIE Jia-hui,ZHANG Ying.Progress in Research on Ovarian Cancer and Non-coding RNA[J].Medical Information,2019,(05):39-42.[doi:10.3969/j.issn.1006-1959.2019.05.014]
点击复制

卵巢癌与非编码RNA研究进展()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年05期
页码:
39-42
栏目:
综述
出版日期:
2019-03-01

文章信息/Info

Title:
Progress in Research on Ovarian Cancer and Non-coding RNA
文章编号:
1006-1959(2019)05-0039-04
作者:
揭嘉慧1张 颖2
(1.广东医科大学,广东 湛江 524002;2.广东医科大学附属医院,广东 湛江 524002)
Author(s):
JIE Jia-hui1ZHANG Ying2
(1.Guangdong Medical University,Zhanjiang 524002,Guangdong,China;2.the Affiliated Hospital of Guangdong Medical University,Zhanjiang 524002,Guangdong,China)
关键词:
卵巢癌非编码RNAncRNAs肿瘤抑制因子
Keywords:
Ovarian cancerNon-coding RNAncRNAsTumor suppressor
分类号:
R737.31
DOI:
10.3969/j.issn.1006-1959.2019.05.014
文献标志码:
A
摘要:
卵巢癌是全球女性因癌症死亡的第5大病因,尽早明确诊断并积极治疗是改善预后的有效方法。随着测序技术的不断发展,人们发现了大量的种类丰富的非编码RNA。ncRNAs在细菌、真菌和哺乳动物等多种生物体的活动中可作为致癌驱动因子和肿瘤抑制因子,对肿瘤的发生、发展起到调控作用,ncRNA有望成为肿瘤诊治的新型生物标志物和治疗靶点。探索ncRNA可为卵巢癌的研究提供一些系统性新思路。现将卵巢癌相关ncRNA最新研究进展进行综述,并着重讨论微小RNA(miRNA)、长链非编码RNA(lncRNA)及环状RNA(circRNA)在卵巢癌中的作用。
Abstract:
Ovarian cancer is the fifth leading cause of female cancer death in the world. Early diagnosis and active treatment are effective methods to improve prognosis. With the development of sequencing technology, it has been discovered that a large number of non-coding RNA.ncRNAs can be used as carcinogenic driver and tumor suppressor in the activities of bacteria, fungi and mammals. NcRNA is expected to be a new biomarker and therapeutic target for tumor diagnosis and treatment. Exploring ncRNA may provide some systematic new ideas for the study of ovarian cancer. In this paper, the latest research progress of ovarian cancer-related ncRNA is reviewed, and the role of micro-RNA (miRNA), long-chain non-coding RNA (lncRNA)and cyclic RNA (circRNA)in ovarian cancer is emphatically discussed.

参考文献/References:


[1]Siegel RL,Miller KD,Jemal A.Cancer Statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.
[2]Jayson GC,Kohn EC,Kitchener HC,et al.Ovarian cancer[J].Lancet,2014,384(9951):1376-1388.
[3]Sundar S,Neal RD,Kehoe S.Diagnosis of ovarian cancer[J].BMJ,2015(351):h4443.
[4]Anastasiadou E,Jacob LS,Slack FJ.Non-coding RNA networks in cancer[J].Nat Rev Cancer,2018,18(1):5-18.
[5]Dalmay T,Edwards DR.MicroRNAs and the hallmarks of cancer[J].Onco gene,2006,25(46):6170-6175.
[6]Guttman M,Rinn JL.Modular regulatory principles of large non-coding RNAs[J].Nature,2012,482(7385):339-346.
[7]Memczak S,Jens M,Elefsinioti A,et al.Circular RNAs are a large class of animal RNAs with regulatory potency[J].Nature,2013,495(7441):333-338.
[8]Esteller M.Non-coding RNAs in human disease[J].Nat Rev Genet,2011,12(12):861-874.
[9]St Laurent G,Wahlestedt C,Kapranov P.The Landscape of long noncoding RNA classification[J].Trends Genet,2015,31(5):239-251.
[10]Dhahbi JM,Spindler SR,Atamna H,et al.Deep Sequencing of Serum Small RNAs Identifies Patterns of 5′tRNA Half and YRNA Fragment Expression Associated with Breast Cancer[J].Biomark Cancer,2014(6):37-47.
[11]Venkatesh T,Suresh PS,Tsutsumi R.Non-coding RNAs:Functions and applications in endocrine-related cancer[J].Mol Cell Endocrinol,2015(416):88-96.
[12]Braicu C,Catana C,Calin GA,et al.NCRNA combined therapy as future treatment option for cancer[J].Curr Pharm Des,2014,20(42):6565-6574.
[13]Hayes J,Peruzzi PP,Lawler S.MicroRNAs in cancer:biomarkers, functions and therapy[J].Trends Mol Med,2014,20(8):460-469.
[14]Chen Y,Fu LL,Wen X,et al.Oncogenic and tumor suppressive roles of microRNAs in apoptosis and autophagy[J].Apoptosis,2014,19(8):1177-1189.
[15]Bagnoli M,Canevari S,Califano D,et al.Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study[J].Lancet Oncol,2016,17(8):1137-1146.
[16]Cramer DW,Elias KM.A prognostically relevant miRNA signature for epithelial ovarian cancer[J].Lancet Oncol,2016,17(8):1032-1033.
[17]Mak CS,Yung MM,Hui LM,et al.MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis[J].Mol Cancer, 2017,16(1):11.
[18]Barbier J,Chen X,Sanchez G,et al.An NF90/NF110-mediated feedback amplification loop regulates dicer expression and controls ovarian carcinoma progression[J].Cell Res,2018,28(5):556-571.
[19]Elias KM,Fendler W,Stawiski K,et al.Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer[J].Elife,2017(6):e28932.
[20]Shah JS,Gard GB,Yang J,et al.Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer[J].Gynecol Oncol,2018,148(1):181-188.
[21]Ulitsky I.Evolution to the rescue: using comparative genomics to understand long non-coding RNAs[J].Nat Rev Genet,2016,17(10):601-614.
[22]Mitra R,Chen X,Greenawalt EJ,et al.Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition[J].Nat Commun,2017,8(1):1604.
[23]Liang H,Yu T,Han Y,et al. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression[J].Mol Cancer,2018,17(1):119.
[24]Teschendorff AE,Lee SH,Jones A,et al.HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer[J].Genome Med,2015(7):108.
[25]Chen Y,Du H,Bao L,et al.LncRNA PVT1 promotes ovarian cancer progression by silencing miR-214[J].Cancer Biol Med,2018,15(3):238-250.
[26]Li N,Zhan X,Zhan X.The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes[J].Gynecol Oncol,2018,150(2):343-354.
[27]Bachmayr-Heyda A,Reiner AT,Auer K,et al.Correlation of circular RNA abundance with proliferation--exemplified with colorectal and ovarian cancer,idiopathic lung fibrosis,and normal human tissues[J].Sci Rep,2015(5):8057.
[28]Ahmed I,Karedath T,Andrews SS,et al.Altered expression pattern of circular RNAs in primary and metastatic sites of epithelial ovarian carcinoma[J].Oncotarget,2016,7(24):36366-36381.
[29]Liu N,Zhang J,Zhang LY,et al.CircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer[J].Eur Rev Med Pharmacol Sci,2018,22(12):3713-3718.

相似文献/References:

[1]杨廷双.卵巢癌患者经CT检查和MRI检查的临床效果对比[J].医学信息,2018,(07):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
 YANG Ting-shuang.Comparison of Clinical Effects between CT and MRI in Patients with Ovarian Cancer[J].Medical Information,2018,(05):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
[2]沈云志,王毅军.miRNA及LncRNA在器官移植免疫排斥中作用的研究进展[J].医学信息,2019,(02):43.[doi:10.3969/j.issn.1006-1959.2019.02.015]
 SHEN Yun-zhi,WANG Yi-jun.Advances in the Role of miRNA and LncRNA in Immune Rejection of Organ Transplantation[J].Medical Information,2019,(05):43.[doi:10.3969/j.issn.1006-1959.2019.02.015]
[3]林斯婕,吴 璇,覃 桓,等.卵巢癌合并2型糖尿病发生的危险因素分析[J].医学信息,2019,(05):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
 LIN Si-jie,WU Xuan,QIN Huan,et al.Analysis of Risk Factors for Ovarian Cancer Complicated with Type 2 Diabetes[J].Medical Information,2019,(05):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
[4]李思文,张 燕.不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究[J].医学信息,2019,(07):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
 LI Si-wen,ZHANG Yan.Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer[J].Medical Information,2019,(05):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
[5]许书凡,庞 华.18F-FDGPET/CT在卵巢癌中的应用研究[J].医学信息,2019,(08):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
 XU Shu-fan,PANG Hua.Research on the Application of 18F-FDGPET/CT in Ovarian Cancer[J].Medical Information,2019,(05):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]

更新日期/Last Update: 2019-03-01